Skip to main content
SpringerLink
Log in

Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients

  • Reproductive Medicine
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Background

The present study was designed to determine the effect of oral contraceptives (OCP) and OCP plus spironolactone (Sp) on plasma soluble CD40L levels in polycystic ovary syndrome (PCOS) patients.

Methods

Fifty-six women with PCOS were randomized into two treatment protocols: ethinylestradiol + cyproterone acetate (2 mg, EE/CA; n = 28), and EE/CA with spironolactone (Sp; n = 28). Plasma sCD40L levels were measured before and after a 3-month treatment.

Results

Before the initiation of treatment, the sCD40L levels were not significantly different between the groups [EE/CA (1.33 ng/mL) vs. EE/CA + Sp (1.23 ng/mL); P > 0.05]. In the post-treatment period, sCD40L concentrations were increased compared with pre-treatment values in the EE/CA and EE/CA + Sp groups (1.33 vs. 2.70 ng/mL, P = 0.011; and 1.23 vs. 2.41 ng/mL, P = 0.017; respectively).

Conclusion

Increased plasma concentrations of sCD40L are associated with OCP and OCP + Sp treatment regimens in PCOS patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Franks S (1995) Polycystic ovary syndrome. N Engl J Med 333:853–861

    Article  CAS  PubMed  Google Scholar 

  2. Doring A, Frohlich M, Lowel H, Koenig W (2004) Third generation oral contraceptive use and cardiovascular risk factors. Atherosclerosis 172:281–286

    Article  CAS  PubMed  Google Scholar 

  3. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med 344:1527–1535

    Article  CAS  PubMed  Google Scholar 

  4. Karakurt F, Gumus II, Bavbek N, Kargili A, Koca C, Selcoki Y, Ozbek M, Kosar A, Akcay A (2008) Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome. Gynecol Endocrinol 24:491–497

    Article  CAS  PubMed  Google Scholar 

  5. Kebapcilar L, Taner CE, Kebapcilar AG, Sari I (2009) High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 280:187–193

    Article  CAS  PubMed  Google Scholar 

  6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81:19–25

    Google Scholar 

  7. Yalcin AI, Dincer M, Aslan V, Gulbas Z (2002) Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res 25:260–264

    Article  CAS  PubMed  Google Scholar 

  8. Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ (2003) Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. J Clin Endocrinol Metab 88:3867–3873

    Article  CAS  PubMed  Google Scholar 

  9. Mach F, Schonbeck U, Libby P (1998) CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 137 Suppl:S89–S95

    Article  CAS  PubMed  Google Scholar 

  10. André P, Nannizzi-Alaimo L, Prasad SK, Phillips DR (2002) Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106:896–899

    Article  PubMed  Google Scholar 

  11. Oktem M, Ozcimen EE, Uckuyu A, Esinler I, Pamuk B, Bayraktar N, Kulaksizoglu S, Zeyneloglu HB (2009) Polycystic ovary syndrome is associated with elevated plasma soluble CD40 ligand, a marker of coronary artery disease. Fertil Steril 91:2545–2550

    Article  CAS  PubMed  Google Scholar 

  12. Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268

    Article  CAS  PubMed  Google Scholar 

  13. Geraldes P, Gagnon S, Hadjadj S, Merhi Y, Sirois MG, Cloutier I, Tanguay JF (2006) Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: an ER alpha-mediated pathway. Cardiovasc Res 71:566–573

    Article  CAS  PubMed  Google Scholar 

  14. Lahita RG (2000) Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 26:951–968

    Article  CAS  PubMed  Google Scholar 

  15. Rider V, Jones S, Evans M, Bassiri H, Afsar Z, Abdou NI (2001) Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 28:2644–2649

    CAS  PubMed  Google Scholar 

  16. Abdou NI, Rider V, Greenwell C, Li X, Kimler BF (2008) Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial. J Rheumatol 35:797

    CAS  PubMed  Google Scholar 

  17. Stice JP, Knowlton AA (2008) Estrogen, NFkappaB, and the heat shock response. Mol Med 14:517–527

    Article  CAS  PubMed  Google Scholar 

  18. Tsytsykova AV, Tsitsikov EN, Geha RS (1996) The CD40L promoter contains nuclear factor of activated T cells-binding motifs which require AP-1 binding for activation of transcription. J Biol Chem 271:3763–3770

    Article  CAS  PubMed  Google Scholar 

  19. Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M (2002) Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99:520–525

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest statement

No conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Bozyaka Training and Research Hospital, Izmir, Turkey

    Levent Kebapcilar, Oktay Bilgir, Ahmet Alacacioglu, Yasar Yildiz, Arif Yuksel & Ismail Sari

  2. Izmir Aegean Obstetrics and Gynecology Teaching Hospital, Izmir, Turkey

    Cuneyt Eftal Taner & Ayse Gul Kebapcilar

  3. Department of Biochemistry, Adnan Menderes University School of Medicine, Aydın, Turkey

    Didem L. Kozaci

Authors
  1. Levent Kebapcilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oktay Bilgir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cuneyt Eftal Taner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayse Gul Kebapcilar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Didem L. Kozaci
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ahmet Alacacioglu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yasar Yildiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Arif Yuksel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ismail Sari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Levent Kebapcilar.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kebapcilar, L., Bilgir, O., Taner, C.E. et al. Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients. Arch Gynecol Obstet 281, 539–543 (2010). https://doi.org/10.1007/s00404-009-1189-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-009-1189-7

Keywords

Search

Navigation